Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Jun

Today In Oncology

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers

Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs

Long-Term Outcomes With SABR in Primary Kidney Cancer